Literature DB >> 24758251

Differences in respiratory-induced pancreatic tumor motion between 4D treatment planning CT and daily cone beam CT, measured using intratumoral fiducials.

Eelco Lens1, Astrid van der Horst, Petra S Kroon, Jeanin E van Hooft, Raquel Dávila Fajardo, Paul Fockens, Geertjan van Tienhoven, Arjan Bel.   

Abstract

BACKGROUND: In radiotherapy, the magnitude of respiratory-induced tumor motion is often measured using a single four-dimensional computed tomography (4DCT). This magnitude is required to determine the internal target volume. The aim of this study was to compare the magnitude of respiratory-induced motion of pancreatic tumors on a single 4DCT with the motion on daily cone beam CT (CBCT) scans during a 3-5-week fractionated radiotherapy scheme. In addition, we investigated changes in the respiratory motion during the treatment course.
MATERIAL AND METHODS: The mean peak-to-peak motion (i.e. magnitude of motion) of pancreatic tumors was measured for 18 patients using intratumoral gold fiducials visible on CBCT scans made prior to each treatment fraction (10-27 CBCTs per patient; 401 CBCTs in total). For each patient, these magnitudes were compared to the magnitude measured on 4DCT. Possible time trends were investigated by applying linear fits to the tumor motion determined from daily CBCTs as a function of treatment day.
RESULTS: We found a significant (p ≤ 0.01) difference between motion magnitude on 4DCT and on CBCT in superior-inferior, anterior-posterior and left-right direction, in 13, 9 and 12 of 18 patients, respectively. In the anterior- posterior and left-right direction no fractions had a difference ≥ 5 mm. In the superior-inferior direction the difference was ≥ 5 mm for 17% of the 401 fractions. In this direction, a significant (p ≤ 0.05) time trend in tumor motion was observed in 4 of 18 patients, but all trends were small (- 0.17-0.10 mm/day) and did not explain the large differences in motion magnitude between 4DCT and CBCT.
CONCLUSION: A single measurement of the respiratory-induced motion magnitude of pancreatic tumors using 4DCT is often not representative for the magnitude during daily treatment over a 3-5-week radiotherapy scheme. For this patient group it may be beneficial to introduce breath-hold to eliminate respiratory-induced tumor motion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24758251     DOI: 10.3109/0284186X.2014.905699

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  19 in total

1.  Assessment with cone-beam computed tomography of intrafractional motion and interfractional position changes of resectable and borderline resectable pancreatic tumours with implanted fiducial marker.

Authors:  Shingo Ohira; Masaru Isono; Yoshihiro Ueda; Takero Hirata; Reiko Ashida; Hidenori Takahashi; Masayoshi Miyazaki; Masaaki Takashina; Masahiko Koizumi; Teruki Teshima
Journal:  Br J Radiol       Date:  2017-03-03       Impact factor: 3.039

2.  Quantifying Allowable Motion to Achieve Safe Dose Escalation in Pancreatic SBRT.

Authors:  Yijun Ding; Warren G Campbell; Moyed Miften; Yevgeniy Vinogradskiy; Karyn A Goodman; Tracey Schefter; Bernard L Jones
Journal:  Pract Radiat Oncol       Date:  2019-04-02

3.  An evaluation of motion mitigation techniques for pancreatic SBRT.

Authors:  Warren G Campbell; Bernard L Jones; Tracey Schefter; Karyn A Goodman; Moyed Miften
Journal:  Radiother Oncol       Date:  2017-05-29       Impact factor: 6.280

4.  Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management-A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study.

Authors:  Hrvoje Kaučić; Domagoj Kosmina; Dragan Schwarz; Andreas Mack; Hrvoje Šobat; Adlan Čehobašić; Vanda Leipold; Iva Andrašek; Asmir Avdičević; Mihaela Mlinarić
Journal:  Cancers (Basel)       Date:  2022-05-29       Impact factor: 6.575

Review 5.  The role of imaging in the clinical practice of radiation oncology for pancreatic cancer.

Authors:  Eugene J Koay; William Hall; Peter C Park; Beth Erickson; Joseph M Herman
Journal:  Abdom Radiol (NY)       Date:  2018-02

6.  Tailoring four-dimensional cone-beam CT acquisition settings for fiducial marker-based image guidance in radiation therapy.

Authors:  Peng Jin; Niek van Wieringen; Maarten C C M Hulshof; Arjan Bel; Tanja Alderliesten
Journal:  J Med Imaging (Bellingham)       Date:  2018-01-12

7.  Feasibility of automated 3-dimensional magnetic resonance imaging pancreas segmentation.

Authors:  Shuiping Gou; Percy Lee; Peng Hu; Jean-Claude Rwigema; Ke Sheng
Journal:  Adv Radiat Oncol       Date:  2016-05-30

8.  Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run.

Authors:  Eva Versteijne; Eelco Lens; Astrid van der Horst; Arjan Bel; Jorrit Visser; Cornelis J A Punt; Mustafa Suker; Casper H J van Eijck; Geertjan van Tienhoven
Journal:  Strahlenther Onkol       Date:  2017-06-12       Impact factor: 3.621

9.  Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study.

Authors:  Eva Versteijne; Oliver J Gurney-Champion; Astrid van der Horst; Eelco Lens; M Willemijn Kolff; Jeroen Buijsen; Gati Ebrahimi; Karen J Neelis; Coen R N Rasch; Jaap Stoker; Marcel van Herk; Arjan Bel; Geertjan van Tienhoven
Journal:  Radiat Oncol       Date:  2017-03-23       Impact factor: 3.481

10.  Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer.

Authors:  Konstantina Karava; Stefanie Ehrbar; Oliver Riesterer; Johannes Roesch; Stefan Glatz; Stephan Klöck; Matthias Guckenberger; Stephanie Tanadini-Lang
Journal:  Radiat Oncol       Date:  2017-11-09       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.